title: Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins.
abstract: Oxidized cholesterol is present in significant quantities in the typical Western diet. When ingested, oxidized cholesterol is absorbed by the small intestine and incorporated into both chylomicrons and LDL, resulting in LDL that is more susceptible to further oxidation. Feeding studies in animal models and epidemiological studies in humans have suggested that oxidized cholesterol in the diet increases the development of atherosclerosis. In this study, we determined the effect of ezetimibe, a drug that inhibits small intestinal absorption of cholesterol, on the levels of oxidized cholesterol in the serum after a test meal containing oxidized cholesterol. We demonstrate that ezetimibe, 10 mg per day for 1 month, markedly reduced the levels (50% decrease) of oxidized cholesterol in the serum after feeding a test meal containing either alpha-epoxy cholesterol or 7-keto cholesterol, two of the predominant oxidized cholesterols found in the diet. Moreover, the decrease in oxidized cholesterol in the serum was attributable to a decrease in the incorporation of dietary oxidized cholesterol into both chylomicrons and LDL. Because there was no decrease in postprandial triglyceride levels, we conclude that this decrease in oxidized cholesterol levels in the serum is attributable to decreased absorption and not to enhanced clearance. Whether this decrease in oxidized cholesterol absorption prevents or delays the development of atherosclerosis remains to be determined.
authors.affiliation: Department of Veterans Affairs Medical Center, University of California, San Francisco, CA, USA. ilona.staprans@ucsf.edu
authors.forename: Ilona
authors.initials: I
authors.lastname: Staprans
authors.forename: Xian-Mang
authors.initials: XM
authors.lastname: Pan
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Rapp
authors.forename: Arthur H
authors.initials: AH
authors.lastname: Moser
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Feingold
mesh_terms: D000042:Absorption; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D050197:Atherosclerosis / Q000473:pathology; D001384:Azetidines / Q000494:pharmacology*; D002784:Cholesterol / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000378:metabolism*; D002914:Chylomicrons; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008074:Lipoproteins / Q000097:blood / Q000737:chemistry*; D008297:Male; D010100:Oxygen / Q000737:chemistry; D019518:Postprandial Period; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D002791:Cholesterol, Dietary; D002914:Chylomicrons; D008055:Lipids; D008074:Lipoproteins; D002784:Cholesterol; D000069438:Ezetimibe; D010100:Oxygen